ImmuPHAGE™ is an in vitro cell model of human alveolar macrophages that facilitates the investigation of complex interactions occurring between inhaled compounds and immune cells in the deep lung. ImmuPHAGE™ can evaluate the impact of a wide range of substances on the human lungs
Functional characteristics
Phenotypic Characteristics
ImmuPHAGE™ features human alveolar macrophage-like cells that closely mirror the physiological and functional attributes of native tissue-resident cells. This model can provide a detailed understanding of the immune processes found in the small airways, including particle clearance, inflammation response, and changes in cell function (e.g. foamy macrophages).
More than a tool for just assessing cell viability, ImmuPHAGE™ provides a profound insight into the impact of chemicals and particles on human alveoli. This patented technology serves as an invaluable asset to diverse sectors, including cosmetics, tobacco, fragrances, agri-chemicals, pharmaceuticals, and academic research. Its ethical and streamlined approach can, in certain scenarios, entirely replace animal testing or significantly reduce the requisite number of animals. ImmuPHAGE™ marks a revolutionary stride in promoting humane research methodologies
ImmuPHAGE™ is accessible as part of ImmuONE’s service packages and can also be procured in plate or vial format.
Alveolar macrophages are often the first cells to respond to an inhaled substance in the deep lung. Their reactions are key determinants of how inhaled substances affect the lungs.
At ImmuONE, we strive to provide relevant immunological and biochemical readouts that can be linked to mechanisms of toxicity. Most alternative cell platforms only indicate cell viability, but ImmuPHAGE™ delves much deeper, offering a unique insight into the impact of chemicals and particles on human alveoli.
In addition, ImmuONE’s scientists are highly specialised in lung alveolar interactions and can provide expert analysis of the results elicited by ImmuPHAGE™. We can benchmark results for a new compound against our reference database to put test results in context, helping our clients answer safety questions with confidence.
This versatile immune model can be applied to problems faced by a range of industries i.e., chemicals, consumer products, pharmaceuticals and many others.
ImmuPHAGE™ is optimised to assess the safety risks of different products, closely mimicking the effects observed in human lungs. It highlights lower airway immune processes, i.e., particle clearance, inflammation, cell functionality and morphological changes (i.e. foamy macrophages) promoting the advancement of ethical and streamlined evaluation techniques.
The model is composed of alveolar macrophage-like cells assembled in vitro in well plates, that closely represent the form and function of human cells. Substances are added to the well plates, and adverse responses can then be evaluated. ImmuPHAGE™ is fully validated and characterised for cell structure & viability, phagocytic activity and cytokine response. ImmuPHAGE™ is available for purchase as a product and as part of ImmuONE’s service packages.
Watch our video below to see how to use ImmuPHAGE™
Inhalation studies Cytotoxicity Cell health and functionality Morphometric assessment Macrophage polarisation Inflammation response assessments Inhalation studies Cytotoxicity Cell health and functionality Morphometric assessment Macrophage polarisation Inflammation response assessments 
Early detection of pulmonary ADC toxicity using ImmuONE’s morph_ONE™ high-content imaging assay of alveolar macrophages to improve safety and efficacy in ADC drug development.
Immune cells are reshaping inhalation toxicology by offering deeper insights into respiratory and systemic effects of tested compounds. In the second ImmuBYTES webinar, ‘Immune cells
A UK biotech start-up with a 3D human lung model that provides an alternative to animal testing has raised a further £600,000 from the Midlands
Make Every Breath Safe
Sycamore House
16 Leyden Road
Stevenage, Hertfordshire, UK
SG1 2BP
Copyright 2025 ImmuONE.
All rights reserved.